Email this article Anticoagulant therapy in patients with atrial fibrillation and reduced kidney function of diabetic and non-diabetic etiologies
- Authors: Sokolova AA1, Daabul IS1, Tsarev IL1, Napalkov DA1, Fomin VV1
-
Affiliations:
- ФБГОУ ВО «Первый МГМУ им. И.М. Сеченова» Минздрава России
- Issue: Vol 89, No 12 (2017)
- Pages: 10-14
- Section: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/32289
- DOI: https://doi.org/10.17116/terarkh2017891210-14
- ID: 32289
Cite item
Full Text
Abstract
Aim. To evaluate the efficacy and safety of direct oral anticoagulants (DOACs) in patients with atrial fibrillation (AF) and stages I-III chronic kidney disease (CKD). Subjects and methods. The cohort parallel-group study included 92 patients with AF and stages I-III diabetic and non-diabetic CKD, who were treated with DOACs (dabigatran, rivaroxaban, or apixaban) and vitamin K antagonists (warfarin). The follow-up duration was 12 months. Results. Thromboembolic events and bleeding, which required patient hospitalization or blood transfusions, were not recorded during 1-year follow-up. There was no clinically significant progression of CKD in the groups of therapy with vitamin K antagonists or DOACs. Just the same, a more intense decrease in glomerular filtration rate and a high rate of hemorrhagic complications were revealed in the subgroup of patients with diabetes mellitus (DM) versus those with non-diabetic CKD. Conclusion. In patients with non-valvular AF and diabetic and non-diabetic CKD, the use of DOACs effectively and safely prevents thromboembolic events, irrespective of the stage of CKD. At the same time, in patients taking anticoagulants, CKD progresses more rapidly in the presence of DM than in its absence, regardless of a specific anticoagulant. Hemorrhagic complications are more common in patients with AF, DM, and CKD, which requires more frequent monitoring of their kidney function.
Full Text
##article.viewOnOriginalSite##About the authors
A A Sokolova
ФБГОУ ВО «Первый МГМУ им. И.М. Сеченова» Минздрава РоссииМосква, Россия
I S Daabul
ФБГОУ ВО «Первый МГМУ им. И.М. Сеченова» Минздрава РоссииМосква, Россия
I L Tsarev
ФБГОУ ВО «Первый МГМУ им. И.М. Сеченова» Минздрава РоссииМосква, Россия
D A Napalkov
ФБГОУ ВО «Первый МГМУ им. И.М. Сеченова» Минздрава РоссииМосква, Россия
V V Fomin
ФБГОУ ВО «Первый МГМУ им. И.М. Сеченова» Минздрава РоссииМосква, Россия
References
- Westendorf J, Ageno W. Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism. Thromb Haemost. 2014;16:113-128.
- Рекомендации. Диагностика и лечение фибрилляции предсердий / Российское кардиологическое общество, Всероссийское научное общество специалистов по клинической электрофизиологии, аритмологии и кардиостимуляции, Ассоциация сердечно-сосудистых хирургов — Москва 2012.
- ACC/AHA Clinical Performance and Quality Measures for Adults With Atrial Fibrillation or Atrial FlutterA Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures / Paul A. Heidenreich, MD, MS, FACC, FAHA;Penelope Solis, JD;N. A. Mark Estes, III, MD, FACC, FAHA;Gregg C. Fonarow, MD, FACC, FAHA;Corrine Y. Jurgens, PhD, RN, ANP, FAHA;Joseph E. Marine, MD, FACC;David D. McManus, MD, MS, FACC, FAHA, FHRS;Robert L. McNamara, MD, MHS, FACC — J Am Coll Cardiol. 2016. https://doi.org/10.1016/j.jacc.2016.03.521
- EHRA PRACTICAL GUIDE / Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation / Updated European Heart Rhythm Association, European society of cardiology — Europace. https://doi.org/10.1093/europace/euv309
- Lip GYH, Laroche C, Popescu MI, Rasmussen LH, Vitali-Serdoz L, Petrescu L, Darabantiu D, Crijns HJGM, Kirchhof P, Vardas P, Tavazzi L, Maggioni AP and Borani G. Prognosis and treatment of atrial fibrillation patients by European cardiologists:One Year Follow-up of the EUROobservational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF Pilot Registry. Eur Heart J 2014;35:3365-3376;Fumagalli S, Said SAM, Laroche C, Gabbai D, Marchionni M, Boriani G, Maggioni AP, Popescu MI, Rasmussen LH, Crijns HJGM, Lip GYH on behalf of the EORP-AF Investigators. Age-related differences in presentation treatment and outcome in patients with atrial fibrillation in Europe. J Am Coll Cardiol. 2015;1:326-334.
- Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular AF. N Engl J Med. 2011;365:883-891.
- Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with AF. N Engl J Med. 2011;365:981-992.
- Даабуль И.С., Соколова А.А., Напалков Д.А. Возможности современной антикоагулянтной терапии у пациентов с неклапанной этиологией фибрилляции предсердий и хронической болезнью почек. Рациональная фармакотерапия в кардиологии. 2016;12(5):595-602.
- Connolly SJ, Eikelboom J, Joyner C, Diener H-C, Hart R, Golitsyn S, et al. Dabigatran versus warfarin in patients with AF. N Engl J Med. 2009;361:1139-51.
- Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular AF. N Engl J Med. 2011;365:883-891.
- Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, t al. Apixaban versus warfarin in patients with AF. N Engl J Med. 2011;365:981-992.
